Antibody therapy for acute lymphoblastic leukemia

Current Hematologic Malignancy Reports

Volumn 7, Issue 2, 2012, Pages 153-159

  Portell, Craig A ^a   Advani, Anjali S ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Alemtuzumab; Antibody directed therapy; Blinatumomab; CD19; CD20; CD22; CD52; Epratuzumab; Inotuzumab ozogamicin; Rituximab

Indexed keywords

ALEMTUZUMAB; BISPECIFIC ANTIBODY; BLINATUMOMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD52 ANTIGEN; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; RITUXIMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG EFFICACY; FEVER; FLOW CYTOMETRY; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER FUNCTION TEST; NEUTROPENIA; OVERALL SURVIVAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE;

EID: 84860833711     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0120-7     Document Type: Review

References (33)

1. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ ECOG E2993. Blood. 2005;106:3760-7. (Pubitemid 41739010)
2. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944-50. (Pubitemid 46220637)
3. Paietta E, Li X, Richards S, et al. Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B-Lineage (B-Lin) all patients (pts) on the MRC UKALLXII/ECOG2993 intergroup trial [abstract]. Proc ASH. 2008;112:1907. http://bloodjournal. hematologylibrary.org.
4. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098-107. Lists clinical characteristics ofCD19, CD20, CD22, and CD33 expression in ALL.
5. Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor Blineage acute lymphoblastic leukemia. Blood. 2009;113:6330-7. CD20 expression denotes a poor prognosis in precursor B-ALL.
6. Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A pediatric oncology group study. Blood. 1997;89:3960-6. (Pubitemid 27220939)
7. Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982-8.
8. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880-9. Rituximab use with HyperCVAD during induction alleviates the adverse prognosis of CD20 expression in Philadelphia chromosome negative B-ALL.
9. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-Lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. [abstract]. Proc ASH. 2010;116:170.http://bloodjournal. hematologylibrary.org.
10. Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116-23. (Pubitemid 43156313)
11. Poe JC, Fujimoto Y, Hasegawa M, et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol. 2004;5:1078-87. (Pubitemid 41057728)
12. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008;113:2714-23.
13. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10:5327-34. (Pubitemid 39100467)
14. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study. J ClinOncol. 2008;26:3756-62. Early study with epratuzumab in childhood ALL showing limited toxicity and early promise.
15. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a children's oncology group study[corrected]. J Clin Oncol. 2008;26:3971-8.
16. Raetz EA, Cairo MS, Borowitz MJ, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children's Oncology Group (COG) study ADVL04P2 [abstract]. Proc ASH. 2011;118:573. http://bloodjournal. hematologylibrary.org.
17. de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicinconjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2011; In press.
18. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21:2240-5. (Pubitemid 350011695)
19. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non- Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085-93. IO use in relapsed and refractory NHL had limited toxicity with 68 % ORR in follicular lymphoma. 20. Jabbour E, O'Brien S, Thomas D, et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin,produces complete response (CR) plus complete marrow response (mCR) of greater than 50 % in refractory relapse (R-R) acute lymphocytic leukemia (ALL) [abstract]. Proc ASCO. 2011;29:6507. http://www.asco.org
20. Watanabe T, Masuyama J-I, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol. 2006;120:247-59. (Pubitemid 44175899)
21. Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645-51.
22. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260-70.
23. Angiolillo AL, Yu AL, Reaman G, et al. A phase II study of campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a children's oncology group report. Pediatr Blood Canc. 2009;53:978-83.
24. Stock W, Sanford B, Lozanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult Acute Lymphoblastic Leukemia (ALL): final phase I results of a Cancer and Leukemia Group B study (CALGB 10102) [abstract]. Proc ASH. 2009;114:838.
25. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18:385-97.
26. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317:1255-60.
27. Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50:886-91.
28. Brischwein K, Parr L, Pflanz S, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother. 2007;30:798-807. (Pubitemid 350295358)
29. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very Low doses of a T cell-engaging antibody. Science. 2008;321:974-7.
30. Topp M.S.,Kufer P.,Gökbuget N.,et al.,Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival,J Clin Oncol, 20111 29,2493-8
31. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-8. Blinatumomab is well tolerated and efficacious in MRD-positive B-ALL. 32. Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25:181-4.
32. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med. 2011;365:725-33. First description of CAR therapy in CLL.
33. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.